Everything above comes from Nervgen Pharma Corp.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted. This company files in CAD. Figures are converted to US dollars at $1.00 = 1.4258 CAD, the current rate, applied to every period alike — so growth and margins are the company’s own and not the exchange rate’s.

Not reported by this filer: Total Revenue, Cost of Revenue, Gross Profit, SG&A Expense, Operating Income, Profit Before Tax, Interest Expense, Income Tax Expense, Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Short-term Investments, Inventory, Long-term Debt (noncurrent), Long-term Debt (current), Short-term Borrowings, Borrowings (total), Finance Lease (current), Finance Lease Liabilities (total), Finance Lease (noncurrent), Capital Expenditures, Dividends paid, Impairments, Share Repurchases, Change in Inventories, Change in Receivables, Change in Payables, Change in Payables and Accruals, Change in Customer Advances, Change in Other Operating Capital, Change in Working Capital, Accounts Payable, and Acquisitions. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.